Null models for the effect of combination therapies are widely used to evaluate synergy and antagonism of drugs. Due to the relevance of null models, their suitability is continuously discussed. Here, we contribute to the discussion by investigating the properties of five null models. Our study includes the model proposed by David J. Hand, which we refer to as Hand model. The Hand model has been introduced almost 20 years ago but hardly was used and studied. We show that the Hand model generalizes the principle of dose equivalence compared to the Loewe model and resolves the ambiguity of the Tallarida model. This provides a solution to the persisting conflict about the compatibility of two essential model properties: the sham combination principle and the principle of dose equivalence. By embedding several null models into a common framework, we shed light in their biochemical validity and provide indications that the Hand model is biochemically most plausible. We illustrate the practical implications and differences between null models by examining differences of null models on published data.
Introduction
Combination drug therapy is an advancing field of research in oncology, anesthesiology and immunology (Mao et al., 2011; Dahl et al., 2014; Bansal et al., 2014; Hu et al., 2016; Ahn & Root, 2017; Eser & Jänne, 2018) .
Treatments with multiple drugs are studied to distribute side effects and minimize toxicity while attaining the full efficacy (Maguire & France, 2018) . The discovery of synergistic combinations can enhance the development of multi-drug therapies and was ranked second place in the principles of combination therapy after " decreased toxicity without decreased efficacy " (Levin & Harris, 1975) . The term 'combination' refers to the choice of pairing agents A and B, to their specific concentration ratio as well as to their explicit doses. In the following we will use the terms drug and agent interchangeable.
Synergy is detected and quantified via the comparison of an experimentally obtained effect and the mathematical reference effect of a null model. If the measured effect to a combination therapy exceeds the reference effect based on the measured effects of the individual drugs, the dose pair is considered synergistic, otherwise antagonistic. In order to quantitatively assess the level of synergy, concepts such as combination indices (Chou & Talalay, 1984) or tools of statistical analysis (Tallarida et al., 1989; Hennessey et al., 2010) were introduced.
A careful choice of the null model used to study synergy is important to not over-interpret results of drug combination studies (see, e.g., (Palmer & Sorger, 2017) for a study where drug independence was able to explain data rather than synergy or additivity). However, this choice requires a detailed understanding of the null models and the differences between them.
Applied in combination, the single effects of an A-dose and a B-dose are expected to add up in a way the null model specifies. Although there exist cases in which the simple algebraic sum of the effects may serve as a null model (Slinker, 1998) , in general this sum will exceed the maximal possible effect, e.g., when the effect is measured in percentage of bound agents. A variety of null models has been introduced in the past and each model tries to provide a plausible concept of additivity that can be biochemically justified. Conceptually, effect-based strategies and dose-effect based strategies are distinguished. In the established Bliss model (Bliss, 1939) , normalized effects are interpreted as probabilities of stochastically independent events, e.g., the event of an analgesic binding to a receptor. This effect-based strategy permits an additivity concept according to the addition rule of probabilities. Two agents which act on different components in a biochemical cascade can be modeled in this mutually non-exclusive way (e.g., the HIV-1 entry inhibitors CoRA and FI (Ahn & Root, 2017) ). However, the implicit assumption of stochastic independence does not hold in case of drugs that act through a similar mechanism. For example, cetuximab and afatinib both inhibit EGFR in the pathway of nonsmall cell lung cancer proliferation (Moran, 2011; Janjigian et al., 2014) . In particular, a sham combination, i.e., a combination of an agent with itself, cannot be described by the Bliss model (Greco et al., 1995) .
Other null models incorporate knowledge on the functional relationship between dose concentration and effect for each single agent over a large range of doses. Such dose-effect based strategies shift the task of designing a null model towards specifying a plausible theory of addition of functions instead of a few numeric values (Geary, 2013) . This functional relationship between dose concentration and effect for the mono-therapies are frequently modeled as Hill curves, which can be fitted to experimental data by standard software (Motulsky & Christopoulos, 2004) . Here, we assume, that the dose-effect curves are increasing and have their maximal numerical value at the saturation level. However, minor changes allow an analogous treatment of decreasing dose-effect curves.
The classical dose-effect based model for mutually exclusive agents was first introduced by Loewe & Muischnek (1926) ; Loewe (1953) and popularized by Berenbaum (1977) ; Chou & Talalay (1984) . It states that doses of drug A and drug B may be linearly converted into each other inducing no modification in effect, where the conversion rate generally depends on the current effect level. For example, if both drugs attain the same maximal effect, then one third of the half-max concentration of A, i.e., the concentration at which the half-max effect is reached, combined with two thirds of the half-max concentration of B is predicted to yield an observed effect of 50%. The set of all dose combinations in the ([a] , [b] )-plane, that are predicted to induce the same effect level is called an isobole, where [a] and [b] are the doses of A and B, respectively. Being an indicator of zero interaction, the isobole separates the plane into a region of synergy of points located below the isobole and a region of antagonism located above it. For the Loewe model isoboles are straight lines, whose slopes are the conversion rates as depicted by the isobologram in Figure 1A .
The Loewe model is broadly accepted and used in cases of constant potency ratio. The potency ratio is the ratio of the effects of two drug and two dose-effect curves are said to have a constant potency ratio if they are identical up to rescaling the dose axis. This means that they are parallel in the representation with a logarithmic dose scale. We will refer to this central but rare case as the 'constant potency ratio case' or the 'case of parallel dose-effect curves'. If the dose-effect-relations are given by Hill curves, two curves exhibit a constant potency ratio, exactly if they coincide in their maximal effects and Hill coefficients. In the prominent cases of a full and a partial agent or different cooperativities, i.e., maximal effect or the Hill coefficient differ, the potency ratio varies across effect levels.
The Loewe model is accepted for parallel dose-effect curves because this case implies that the conversion rate does not depend on the current effect level, i.e., the isoboles for all effect levels in the Loewe model are parallel.
Two principles were extracted from the constant potency ratio case that seem to permit a transfer to the varying potency ratio case: The principle of dose equivalence (Grabovsky & Tallarida, 2004) and the principle of sham combinations (Berenbaum, 1989) . The former states that each A-dose can be assigned a B-equivalent, which induces the same effect. The latter states that, a drug is not expected to synergize in a combination with itself. The sham combination principle is rather specific to mutually exclusive agents and violated by several null models, including the Highest Single Agent (HSA) model, the Bliss model and the Fisher's dosage orthogonality (Russ & Kishony, 2017) .
The attempt to base a null model on coupling both principles for curves of varying potency ratio (Grabovsky & Tallarida, 2004; Tallarida, 2006 Tallarida, , 2011 fails to identify unique isoboles, as objected by Lorenzo & Sánchez-Marin (2006) . This failure has incorrectly been attributed to Loewe as the caption "indeterminate Loewe additivity solution", which Geary uses in (Geary, 2013) While the Loewe model does not lack uniqueness, it is nonetheless justified to doubt its validity in several cases.
Among the critics of its validity in the rather generic case of varying potency ratio one finds Loewe himself (Loewe, 1953) . In particular, skepticism in the case of differing maximal effects when combining a full and a partial agent has led to an increasing amount of competitive models (Greco et al., 1995; van der Borght et al., 2017; Twarog et al., 2016; Wicha et al., 2017) . Experimentalists emphasize that curved rather than straight isoboles are expected (Luszczki, 2008; Geary, 2013) if dose-effect curves are not parallel, which is confirmed by examples of mechanistic models (Bosgra et al., 2009) . To account for these deficits, Hand introduced an alternative and more general non-interaction model (Hand, 2000) , which has unfortunately been overlooked in the reception of synergy detection models. Hand suggests to construct dose-effect curves for combined agents via an ordinary differential equation (ODE) in a way that both agents contribute linearly to the instantaneous gain in effect.
The conflict about the compatibility of sham combination principle and dose equivalence has been persisting for long. In this manuscript, we show how the Hand model can be obtained as a unique limit model of the 
with inverse 
.
If the potency ratio is constant, both curves are identical up to rescaling the dose axis, or equivalently both curves are parallel, when plotted on a logarithmic dose axis.
We denote a combination drug of A and B at fixed ratio λ ∈ [0, 1] by C λ , i.e., one unit [c] of the agent C λ is composed as [c] = λ[a] + (1 − λ) [b] . Accordingly, the treatment with an amount c of the combination drug C λ corresponds to a treatment with a = λc of drug A together with b = (1 − λ)c of drug B.
Favorable properties of a null model
Given the dose-effect curves f A and f B of the single agents, a null model predicts the effect as a function
Two cuts through the two-dimensional effect-surface {(a, b, E(a, b))| a, b ≥ 0} visualize the combined effect (Greco et al., 1995) : Dose-effect curves of combination drugs C λ vertically cut the surface along a ray directed according to the fixed ratio λ, i.e., the combined curve follows
where we sometimes oppress the index λ for readability ( Figure 1B ). Isoboles are horizontal cuts at level x, i.e., level sets of E, projected onto the ([a], [b])−plane ( Figure 1C ).
A null model for drug combinations should ideally possess at least two properties to be biochemically plausible:
(i) The combination of a drug with itself should neither result in synergy nor antagonism, meaning that it does not interact with itself and meets the sham combination principle. In the above notation E satisfies the sham combination principle if for all λ ∈ [0, 1]
Geometrically the isoboles of the effect surface are then straight lines with unit slope.
(ii) The swap of drug A and B should not change the effective results. Mathematically, this implies that E is commutative in A and B, i.e., for all λ ∈ [0, 1]
In addition, a model may satisfy an associative property, which allows to combine combination drugs: The associativity principle is stronger than commutativity, because the latter is contained in the associativity property by the particular choice λ = 0, µ = 1.
Geometrically, associativity means: 
Dose-effect based null models
In this section, we introduced the null models proposed by Loewe, Tallarida and Hand. These null models are based on the dose-effect strategy and rely on the knowledge of the complete dose-effect curve.
The Loewe model
The classical approach for mutually exclusive drug combinations is the Loewe model (Loewe, 1953; Berenbaum, 1977) . As its core, the model postulates that the isoboles are straight (Loewe & Muischnek, 1926) . The isobole at effect level x can thus be characterized as the set of all combinations (a, b) satisfying the Loewe additivity
(3) 
The effect E L (a, b) predicted by the Loewe model for an arbitrary combination (a, b) can be obtained by Figure 1A ). E L is commutative and satisfies the sham combination principle. However, it is only defined for effects x, which are produced by both
The potency ratio α(x), which is geometrically the slope of the isobole, precisely expresses the conversion rate of equivalent doses in the Loewe model. If A and B exhibit a constant potency ratio, then all isoboles in the Loewe model are parallel. Tallarida (2006) , Geary (2013) and others argue that this property is necessary to ensure validity of the Loewe model as "
linear isoboles are valid only if the dose-effect curves of the drugs considered have constant relative potency" (Geary, 2013) . Accordingly, the probable case of a varying potency ratio would prevent the use of the Loewe model.
The Tallarida model
In an attempt to transfer the principles of dose equivalence and sham combination to the case of varying potency ratio, Grabovsky and Tallarida suggested to convert a dose a into an equivalent B-dose f −1 B (f A (a)) generating the same effect f A (a) ( Figure 2 ). Adding this B-equivalent to b should predict the effect via f B (Grabovsky & Tallarida, 2004) , i.e.,
Since the model was further popularized by Tallarida (Tallarida, 2006 (Tallarida, , 2011 , we refer to it as the Tallarida model. Conceptually, the Tallarida model decomposes the total effect x = E T,A→B (a, b) = x A + x B as in the following way: dose a of A individually achieves an effect x A = f A (a) on its lower range of doses, while dose b of B acts on its higher dose range, contributing on top of the effect achieved by A, i.e.,
Note that the model with altered roles of A and B is
The models E T,A→B and E T,B→A might predict a different effect because in general
Accordingly, while the Tallarida model meets the sham combination principle, it does not fulfill the commutation property. The two model predictions E T,A→B (a, b) and E T,B→A (a, b) encompass a range of effect values.
In the following, we will refer to the TallaridaLB model and the TallaridaUB model,
that give a lower and an upper bound to this range.
The Hand model
It remains the problem that the Tallarida top of whatever effect level was reached by" a in equation (4) one needs to "capture the fact that the drugs have their effect simultaneously" (Hand, 2000) . He proposed to construct E by specifying the rate at which the effect is changing. Since the rate is a one dimensional quantity, it is advantageous to assign values to the entire plane of dose pairs by going along rays at fixed ratio λ. More precisely he suggested that the combined curve f AB,λ must satisfy the differential equation
This characterizing equation states that at each effect level both agents contribute linearly to the instantaneous gain in effect of the combined curve. For an arbitrary dose pair (a, b), identify the ratio λ ∈ [0, 1], such that
Using the inverse derivative formula, we express the differential equation (6) as
or in integral representation
The Hand model was constructed to satisfy the sham combination principle and clearly it is commutative in A and B. Hand stresses that if an agent saturates at a lower level than the other, its derivative is set to zero above that level. This is a natural interpretation of (6) given that x is not in the range of either f A or f B . The
Hand model thus comprises the case of a full and a partial agent. Moreover, Hand mentions that the isoboles will be straight in the constant potency ratio case. Coinciding with the Loewe model for this subcase, it is regarded by Hand as a generalization of the Loewe model. We will demonstrate in Section 3.3, that the Loewe model is justified also for cases of varying potency ratio and thus the term "generalization" should be used with care.
Effect-based null models
Alternatives to the dose-effect based null models are effect-based models. These null models require only the knowledge of the effect of the single doses a and b to provide a prediction of the combined effect E(a, b).
Commonly used effect-based models are the Bliss model and the HSA model. The Bliss model (Bliss, 1939) is based on a probabilistic framework, and defines the effect of a drug combination as
For this definition it is necessary, that the greater of the maximum values of the two dose-effect curves, E max,A and E max,B , are normalized to 1. The HSA model, often referred to as Gaddum's non-interaction (Berenbaum, 1989) , is defined as
The Bliss and the HSA model do not fulfill the sham and the associative principle.
For a detailed comparison of the properties of all null models we refer to Section 3.4.1 and Table 1. 3 Results
Mathematical analysis of the Hand model
In this study, we consider five previously published null models. Amongst them, the Hand model is the least well known and studied one. To facilitate an intuitive understanding: we will provide a unified derivation of the Tallarida and the Hand model; and we will introduce the novel concept of effect-sensitivity curves and confirm the additivity principle. Subsequently, we will study the properties of the Hand model for combinations of partial and full agents and its isoboles. The combined dose-effect curve for the mixture C λ is constructed by applying N pieces of dc = da + db. After twice applying dc, the effect level x 0 is attained. Applying a third mixture of da and db successively increases the effect to x 1 and finally x 2 .
Unified derivation of the Tallarida and the Hand model
In the literature, the Tallarida and the Hand model are presented and discussed separately (Grabovsky & Tallarida, 2004; Hand, 2000) . Here, we establish a link and improve the understanding of the Tallarida and the Hand model by providing a unified derivation. By this derivation we extended the original paper's frank justification on addition of rates.
We start from the concept of Tallarida on equivalent doses (5). However, instead of applying a entirely and then b entirely, we apply portions of both, constantly alternating ( Figure 3 ). Formally, we split both doses a and b into N pieces da = a N and db = b N , respectively. In particular it is (7). We define dc := da + db as a small portion of the combination drug C λ . By alternately applying portions da and db, we keep track of how the effect changes. Suppose, we have constructed the dose-effect curve f AB,λ of C λ up to an effect level x 0 , induced by a mixture dose
Applying da elevates the effect level to x 1 = f A ( da + f −1 A (x 0 )) and db subsequently amplifies the effect level 
). By the above procedure we obtain
For N = 1, this procedure yields the Tallarida model. To study N → ∞ we take the first-order Taylor approximation, divide by dc and note that da = λ dc, db = (1 − λ) dc. This yields
In the limit case dc → 0, i.e., an infinite amount of infinitesimal pieces dc, the difference quotient tends to the derivative on the left side in (6) and we obtain the Hand model. Note that the roles of A and B in the derivation may be switched, approaching the same differential equation in the limit. This yields a unique limit model even though each approximative model is ambiguous.
Effect-sensitivity curves and an additivity principle for the Hand model
In the Hand model (6) the instantaneous gain in effect depends on the individual dose-effect curves f A (a) and
, respectively. We term the derivative f A (a), which is measured in effect per dose, its sensitivity. As the functions s A (x) and s B (x) describe the sensitivity of the dose-effect relation subject to the effect level, we term (x, s A (x)) and (x, s B (x)) effect-sensitivity curves. The dose-effect curve f A is then the solution to
The sensitivity is precisely the right-hand side of the autonomous ODE which guides the dynamics of the dose-effect curve, evolving over the dose range instead of time. For Hill curves as in (1) the effect-sensitivity curve is explicitly given by The Hand model specifies the following additivity concept
where the quantities, which are added, are the sensitivities; i.e. the effect-sensitivity curve of the combined agent is a weighted average of the single effect-sensitivity curves with weights according to the mixture ratio ( Figure 4 ). More suggestively, we say that the Hand model summates the dynamics of the single dose-effect curves.
Geometric properties of the Hand model's isoboles
The isoboles of the null model are the basis for assessing synergy and antagonism of drugs. While the Loewe model's isoboles are easily graphically obtained and analytically given in closed form as soon as f −1 A (x) and f −1 B (x) are known, the Hand model's isoboles are nontrivial and might often have to be computed numerically. However, we could show that the Hand isoboles share a characteristic geometric feature: they are always convex (Appendix 5.4). As a consequence, they systematically diminish the region of synergy compared to the Loewe model.
Combination drugs for partial and full agent
In practice the maximal effect of drug A might be smaller than the maximal effect of drug B, meaning that A acts as the partial agent and B as the full agent. Since the construction in the classical Loewe model requires effect levels that are attained by both agents (Loewe, 1953) , this case has motivated to a large extent the search for alternative models (Greco et al., 1995; van der Borght et al., 2017; Twarog et al., 2016; Wicha et al., 2017) .
In the following we assume E max,A < E max,B .
Loewe model for partial and full agent
The Loewe model assigns effect values to all dose pairs (a, b) with b < f −1 B (E max,A ) ( Figure 5A ). In fact, the slope of the isoboles approaches 0 as the effect level approaches E max,A . This phenomenon arises because the Hill curve f A saturates asymptotically. Hence the strip in the ([a], [b] )-plane that is bounded by the horizontal
is covered entirely by Loewe isoboles. The horizontal limit isobole b = f −1 B (E max,A ) coincides with the HSA model's isobole at level E max,A , which suggests to extend the Loewe model by the HSA model.
Hand model for partial and full agent
As shown in (Hand, 2000) , the Hand model comprises the case of a partial agent A and a full agent B. In terms of sensitivities, the effect-sensitivity curve s A is extended by constant zero on the effect domain [E max,A , E max,B ) ( Figure 5B ), i.e. the sensitivity of the combined curve is
If c * (λ) denotes the dose of mixture C λ at which E max,A is attained, then
• for c ≤ c * (λ), the ODE guiding the evolution of f AB,λ is (6).
• For c > c * (λ), the evolution simplifies to the initial value problem
for all a + b ≥ c * a a+b . Accordingly, for effect sizes greater than E max,A only B has an effect and the doseeffect curve for C λ in this regime corresponds to the scaled and shifted dose-effect curve f B . In contrast to the Tallarida model, the effect surface does not copy the dose-effect curve f B in the direction parallel to the B-axis.
Using the integral representation, c * (λ) is explicitly given by Above the partial agent A's maximal effect value its sensitivity is set to 0. As soon as the combined curve passes the curved limit isobole at effect level E max,A it is driven by the full agent alone.
Decomposing the combined dose c * (λ) into its contributions a * (λ) = λc * (λ) and b * (λ) = (1 − λ)c * (λ), the limit
is a monotone continuous function with lim λ→1 b * (λ) = 0. Assuming an underlying mechanistic dynamical model for the effect of the individual drugs, it is plausible to request that the change in effect should only depend on the current effect level. If nothing but the knowledge about the single dose-effect curves is available, it is plausible that the single dynamics predict the dynamics of Figure 6 : Paths for the three null models. The three null models solve equation (12) 
Using E(γ(t)) ≡ x, we obtainγ
The last equality holds because f −1
The calculation (13) shows that the ratioγ A (t) γ B (t) does in fact not depend on t, but is constant for all t. Consequently, γ parametrizes a straight line with the slope given precisely by the potency ratio α(x). It is important to notice, that we did not request the isoboles to be straight lines in the first place, however, satisfying (12) forces them to be linear.
The Tallarida model E T,A→B is recovered by following a rectangular path from (0, 0) to (a, b) ( Figure 6B ).
where ⊕ concatenates the paths, i.e. for t ∈ [0, 2]
Then along γ 1 equation (12) integrates to E T,A→B (γ 1 (t)) = f A (ta) and along γ 2 equation (12) with initial
Analogously, the model E T,B→A is obtained by the rectangular path γ 1 (t) = (0, tb), γ 2 (t) = (ta, b).
The Hand model is recovered if we request (12) to hold along combined curves γ(c) = (λc, (1 − λ)c) ( Figure   6C ). In this case we compute by the chain rule
In the constant potency ratio case, (12) admits a solution and all three models coincide. Indeed, for f −1 
Comparison of the mathematical properties of the null models
The null models considered in this study possess different (combinations) of properties. In this section, we collect the available information, present results on the associative principle and outline the implications of our findings. In addition, we study the reference effect values calculated by different null models and prove rigorous orderings.
Properties of the Loewe, the Tallarida and the Hand models
Given a general framework for all three null models, we studied their properties in further detail. A summary is provided in Table 1 . As outlined before,
• the Loewe, the Tallarida and the Hand model meet the sham combination principle (Section 2.3), which is not the case for the Bliss and the HSA model; and Indeed, we could also prove here that
• the Loewe and the Hand model fulfill the strong property of associativity (Appendix 5.3.1).
For drugs with constant potency ratios, the Loewe and Hand model coincide. Furthermore, the Tallarida and the Hand are applicable to a combination of full and partial agents.
Our analysis reveals that the Hand model fulfills all the previously defined favorable properties (see Section 2.2 and (Hand, 2000) ), while all other models only fulfill some of them. As the favorable properties are biochemically motivated, this implies that the Hand model is biochemically most plausible among the considered models.
Systematic inequalities
The assessment of drug synergy or antagonism for a single dose of a combination drug is equivalent to the question: On which side of the isobole corresponding to the observed effect does the measured dose pair lie?
Accordingly, the definition of drug synergy or antagonism depends directly on the isobole, which potentially differ substantially between the null models. For the example shown in Figure 7 , the HSA, the Bliss, and the TallaridaLB model classify a dose pair to be synergistic, while the Loewe, the TallaridaUB, and the Hand model classify it as antagonistic. Note that a null model which predicts effects yields and isobole which is further away from the origin. 
In addition, (i) TallaridaLB is by definition lower than TallaridaUB and (ii) the HSA model predicts systematically lower effects than all other null models, for instance
In summary, following systematic inequalities hold for the reference effect values obtained by the different null models for any combination drug C λ and combination drug concentration c:
Comparison of null models using experimental data
To assess the characteristic features of the different null models in practice, we considered the drug screening data collected by O'Neil et al. (2016) . The dataset reports the effects of 39 cancer cell lines to 38 drug individual drugs and 583 drug combinations of these drugs. Each combination was measured on a 4 by 4 dosing regime.
The proliferation compared to the untreated condition is taken as the readout of the effect. data for the single drug treatments. The Bayesian Information Criterion (BIC) (Schwarz, 1978) was used to select the more suited model.
For a comparison of the null models, we considered the predictions of all tested dose pairs of all tested drug combinations. For the cell line A375, the predictions are visualized in Figure 8 . Besides the systematic inequalities which have been proven in Section 3.4.2, we found:
• Reference effects for different null models were highly correlated. • The Bliss model neither systematically provided lower nor higher reference effects than the Loewe, the TallaridaUB and the Hand model ( Figure 8 ).
Discussion
The Loewe model has persisted for long as the first choice to model additive behavior and its validity is in general accepted in the case of constant potency ratio. Skepticism about the applicability in the case of varying potency ratio case has put forth a large variety of null models. For a full and partial agent the Loewe model is in fact incapable of providing a reference effect in a certain dose range, because the reference relies on a shared effect level of both agents. If both drugs reach the same maximal effect, a Loewe assignment is possible, even if the shapes of the saturation curves are different. This case required further arguments why to doubt the Loewe model's validity. In this manuscript, we showed that the skepticism can be perpetuated only to some extent, see below.
It has been observed that the principle of dose equivalence and the sham combination principle very well characterize the Loewe model in the constant potency ratio case (Berenbaum, 1977; Grabovsky & Tallarida, 2004; Geary, 2013) . They seem promising if one attempts to modify the Loewe reference. The coupling of both principles has served as sufficient condition ("Its [the Loewe equation's] derivation took no account of the shapes of the dose-effect curves" (Berenbaum, 1977) ), necessary condition ("The Loewe additivity rests on" (Foucquier & Guedj, 2015) ) and proof of non-validity (Grabovsky & Tallarida, 2004; Geary, 2013) In summary, the interest in combination drug therapy is steadily increasing and an assessment requires suitable null models. Here, we have compared several established models and have shown that the Hand model is of most versatile use, for its unique assignment, mathematical plausibility, simplicity, conservative prediction and biochemical interpretability.
Appendix

Derivation of the ODE governing the combined dose-effect curve of the Hand model
According to the Hand model, the dose-effect f AB,λ for the combined agent C λ satisfies the ODE
This ODE for the combined dose-effect curve f AB,λ at fixed dose ratio λ can be derived using a Taylor expansion up to first order.
Denote by
) the intermediate and final effect level after applying daand db, respectively. Then the gains in effect due to A, B and their combination are
Dividing by dc yields
If we let tend dc −→ 0, also x 1 → x 0 , the difference quotient approaches
and we get the above ODE.
Effect-sensitivity curves
Derivation of the effect-sensitivity formula for Hill curves
The dose-effect behavior is often modeled by Hill curves. For Hill curves of the form
the derivative is
Thus, for the sensitivity we find
Conversion of dose-effect and effect-sensitivity curves
Starting with a strictly increasing, piecewise differentiable dose-effect function f A , its inverse exists and its sensitivity is given by s
. For a given positive piecewise continuous effect-sensitivity function s A , the inverse f −1 A is obtained by
dy.
Since by this calculation f −1 A is a strictly increasing function, it is injective and its inverse f A exists. Alternatively, f A is obtained as the unique strictly increasing solution of the autonomous ODE x = s A (x), x(0) = E min,A .
In order for the above calculation to be valid, we must assume that if lim x→E min,A s A (x) = 0, the integral 0 1 s A (y) dy is finite. For the class of s A as given by the above formula for Hill curves, this assumption is satisfied, because 1 s A behaves like (x − E min,A ) −γ near E min,A with γ = 1 − 1 n A ∈ (0, 1) and thus integrates to a finite value. Note, that in the limit case n A = ∞, EC 50,A = ∞, such that n EC 50,A = c A , s A behaves like the logistic equation s A (x) = c A (x − E min,A ) (E max,A − x) and the solution x(a) of x = s A (x) approaches E min,A only in the limit a → −∞, not in a finite amount of dose.
Numerically the integral 0 1 s A (y) dy or equivalently the ODE x = s A (x), x(0) = E min,A must be treated with care whenever s A (E min,A ) = 0 because it allows the unfavored constant solution x ≡ E min,A as well as solutions that are initially constant and exit E min,A at an arbitrary dose value.
In the numerical implementation we solved this problem by setting the ODEś initial value to x 0 = ε = 1e-7.
Details can be found in the Appendix 5.8.
Disproof of the associativity property for the Tallarida, the Bliss and the HSA model
(i) The Tallarida model does not satisfy the associativity property. By the choice λ = 0, µ = 1, the associativity property implies commutativity, which the Tallarida model violates.
(ii) For the Bliss model, the case λ = µ = ν = 1 2 , A = B shows that the associative property is violated because
(iii) The HSA model is characterized by isoboles that form a rectangle with the dose axes. If the newly allocated coordinate axes are bent, the isobole will be reshaped to an angle of more than 90 • . The characteristic property is then lost. Moreover, the isobole suggested by applying the HSA model on C λ and C µ encloses the original isobole, resulting in a smaller prediction value. This geometric interpretation of the associative property is displayed in the formal definition as well: From
we conclude that
Proof of congruency of the Hand and the Loewe model assuming constant potency ratio
Let α be the constant potency ratio, i.e., for any effect level x, f −1 A (x) = αf −1 B (x), it holds for the derivatives:
Then by (8) it follows for the combined curve f AB,λ of child agent C λ
Consequently (ii) The formulas for effects E Bliss and E HSA are symmetric in A and B.
(iii) The Loewe isobole equation is symmetric in A and B. The isoboles determine the effect surface uniquely.
Disproof of the commutativity for the Tallarida model
The proof for the asymmetry in the Tallarida model is given in (Lorenzo & Sánchez-Marin, 2006 
Then
Disproof of the sham combination principle for the Bliss and the HSA model
The sham combination principle for the Bliss model is addressed in (Foucquier & Guedj, 2015) . The HSA model predicts
if λ ∈ (0, 1) and f A is strictly increasing.
Proof of the isoboles' convexity in the Hand model
The isoboles obtained from the Hand model are convex. They are strictly convex if and only if f A and f B exhibit a varying potency ratio.
We prove this property of the Hand model using (i) the integral representation (9) and (ii) the associativity property:
(i) Fix an effect level x, which is in the target domain of f A and of f B . Then for any λ ∈ (0, 1), it holds
i.e., the pair (a, b) predicted by the Hand model to generate E H (a, b) = x lies below the Loewe straight isobole.
(ii) To show convexity, apply the same argument with two child agents C λ , C µ instead of A, B and corresponding points
on the isobole at level x. By the associativity property, we can conclude that for any σ ∈ [λ, µ] the point (σc, (1 − σ)c) on the Hand isobole at effect level x lies below the line segment through P 1 and P 2 , completing the proof of the convexity property. Now that the plan was established we carry out the steps.
(ii) We proceed by first proving (15). For readability setÃ = f −1 A (x),B = f −1 B (x). Factoring out c, and multiplying by ABλ −1 (1 − λ) −1 , (15) is equivalent to
Integrating the rates f −1 AB,λ , f −1 A , f −1 B , we get the following representations
Define the second and third integrand as h A (y) and h B (y), respectively. Using the integral representation (9) of the ODE and the identity (z −1 + w −1 ) −1 = zw z+w , which holds for any two positive real numbers: c = 
Substituting (17) and (18), (16) is equivalent to proving: In order to establish this integral inequality, we use Cauchy-Schwarz f, g 2 − f 2 g 2 ≤ 0
for the scalar product f, g :=
x 0 f (y)g(y)dy
where we choose f =
For readability we omit the integral bounds 0, x and the integration variable y when calculating
Furthermore, equality holds in (19) .
which means that f A and f B exhibit a constant potency ratio.
(ii) It remains to prove that (15) indeed assures the convexity of the isobole. Let any three points P 1 = (a 1 , b 1 ), P 2 = (a 2 , b 2 ) and P 3 = (a 3 , b 3 ) lie on the isobole. Rewrite a i = λ i c i , b i = (1 − λ i )c i for λ i = a i a i +b i and c i = λ −1 i a i , upon relabeling we may assume λ 1 < λ 3 < λ 2 . For convexity, it has to be proven that (a 3 , b 3 ) lies inside the triangle ∆ 1 = ∆((0, 0) T , (a 1 , b 1 ) T , (a 2 , b 2 ) T ). The linear transformation On the other hand, all isoboles at effect levels 0 < x < E max,A lie in the domain D. The isoboles at effect levels 0 < x < E max,A cover the domain D. By continuity of E L the limit isobole at the effect level E max,A is forced to be the boundary of the set D, which is the horizontal line {(a, b)|b = b * }.
Estimate on the Error
Numerically, the ODE must not be solved starting in x = 0, since the simulation would result in the unfavored solution which is constant 0. If the ODE is simulated starting in x = , the error for the dose can be approximated by
where we used the inequality of the geometric-arithmetic mean to estimate the integral.
For a Hill curve f A and small, we have
If λ ∈ (0.03, 0.97) and = 10 −k , we may thus approximate the magnitude of the error log 10 (f −1 AB,λ ( )) ≤ 1 + max i∈{A,B} − 1 n i (k + log 10 (W max,i )) + log 10 (d i )
In order for the error to be less than 10 s , k should be chosen as k ≥ max i∈{A,B} ((1 + log 10 (d i ) − s)n i − log 10 (W max,i ))
For example, in case of n A = 2, n B = 3, log 10 (W max,A ) = log 10 (W max,A ) = 5, log 10 (d A ) = 3, log 10 (d B ) = 2, and s = −1, one needs to choose k = 7.
Remark. The estimate can be improved depending on the size of λ. E.g. if λ ∈ (0.3, 0.7), then log 10 (f −1 AB,λ ( )) ≤ 0.1 + max i∈{A,B} − 1 n i (k + log 10 (W max,i )) + log 10 (d i ) and k ≥ max i∈{A,B} ((0.1 + log 10 (d i ) − s)n i − log 10 (W max,i )) .
In the above example, choosing k = 4.3 then suffices. The initial condition was set to ε = 1e-7, a value slightly above the ODE solvers absolute error tolerance. The MATLAB solver ode15s was used with the settings AbsTol = 1e-8, RelTol = 1e-5 and the non-negative option.
Numerical implementation of the Hand model
